NCT07446322 2026-03-04
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Oncolytics Biotech
Phase 2 Not yet recruiting
Oncolytics Biotech
Oncolytics Biotech
University of Southern California